Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

December 7, 2017

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY 43-9006)

The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.

Trial Locations (1)

Multiple Locations